This accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9).
These activities have been designed to meet the educational needs of interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.
Upon completion of these activities, participants should be better able to do the following:
- Identify patients with persistent hypercholesterolemia at particularly high risk for poor cardiovascular outcomes who are appropriate candidates for intensified lipid-lowering regimens
Christie M. Ballantyne, MD, FACP, FACC
Professor of Medicine
Chief, Sections of Cardiovascular Research & Cardiology
Director, The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart & Vascular Center
Marc S. Sabatine, MD, MPH
Chairman, TIMI Study Group
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:
Christie M. Ballantyne, MD, FACP, FACC: Grant/Research: Abbott Diagnostics, Amarin Corporation, American Diabetes Association, American Heart Association, Amgen Inc., Esperion Therapeutics, Inc., Ionis Pharmaceuticals, Inc., National Institutes of Health, Novartis Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics, Sanofi-Synthelabo SA; Consultant: Abbott Diagnostics, Amarin Corporation, Amgen Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Esperion Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Matinas BioPharma Holdings Inc., Merck & Co., Inc., Novartis Corporation, Novo Nordisk Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics, Sanofi-Synthelabo SA
Marc S. Sabatine, MD, MPH: Grant/Research (for Brigham and Women’s Hospital): Amgen Inc., AstraZeneca plc, Daiichi-Sankyo Company, Limited, Eisai Inc., GlaxoSmithKline plc, Intarcia Therapeutics, Inc., Janssen Research and Development, LLC, The Medicines Company, MedImmune, LLC; Merck & Co., Inc., Novartis Corporation, Pfizer Inc., Poxel SA, Takeda Pharmaceuticals, U.S.A., Inc; Consultant: Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, CVS Caremark, Esperion Therapeutics, Inc., Intarcia Therapeutics, Inc., Janssen Research & Development, LLC, The Medicines Company, MedImmune, LLC, Merck & Co., Inc., Novartis Corporation
Rose O’Connor, PhD, CHCP; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.
These activities have been supported by an independent educational grant from Jazz Pharmaceuticals.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Sanofi US and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of the patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of each activity
- Complete the Pre-Activity Questions.
- Read or review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- A physician who achieves a grade of 70% or better on the Postactivity Test and who completes the Evaluation will receive a CME Certificate.
- Any other participant who achieves a grade of 70% or better on the Postactivity Test and who completes the Evaluation will receive a Certificate of Participation.